Cogent Biosciences launches $400M at-the-market offering at $42.39/share to fund bezuclastinib

Filed August 10, 2026 · ~2 min read

Key Changes

• high

  At-the-market offering of up to $400M of common stock through Guggenheim Securities, with shares sold at prevailing market prices on Nasdaq rather than a fixed price. Assuming sales at the August 7, 2026 reference price of $42.39/share, the company would issue 9.4M shares.

  The Offering verify on EDGAR →
• high

  Proceeds will fund development and regulatory activities for bezuclastinib (the lead product candidate) and other candidates, the anticipated commercial launch of bezuclastinib, and general corporate purposes. No specific dollar allocations disclosed.

  Use of Proceeds verify on EDGAR →
• high

  Implied post-offering market capitalization of $8.3B at the $42.39 reference price (195.4M shares outstanding after the offering). New investors experience immediate dilution of $37.68/share, paying $42.39 but receiving $4.71 in net tangible book value per share.

  Dilution verify on EDGAR →